BidaskClub upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a buy rating in a report released on Thursday.
ASND has been the topic of several other research reports. ValuEngine upgraded Ascendis Pharma A/S from a buy rating to a strong-buy rating in a research note on Wednesday, December 5th. Credit Suisse Group boosted their price target on Ascendis Pharma A/S from $80.00 to $86.00 and gave the stock an outperform rating in a research note on Thursday, November 29th. Finally, Zacks Investment Research cut Ascendis Pharma A/S from a buy rating to a hold rating in a research note on Tuesday, November 13th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $77.56.
Shares of ASND traded down $1.43 during midday trading on Thursday, reaching $69.25. 127,923 shares of the company were exchanged, compared to its average volume of 239,337. The stock has a market cap of $2.94 billion, a PE ratio of -15.99 and a beta of 0.86. Ascendis Pharma A/S has a 1-year low of $45.17 and a 1-year high of $76.99.
Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, November 28th. The biotechnology company reported ($0.94) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.23) by $0.29. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. As a group, analysts predict that Ascendis Pharma A/S will post -3.9 EPS for the current year.
A number of institutional investors have recently made changes to their positions in ASND. PNC Financial Services Group Inc. bought a new stake in Ascendis Pharma A/S in the second quarter valued at about $350,000. Glen Harbor Capital Management LLC increased its holdings in Ascendis Pharma A/S by 12.1% in the second quarter. Glen Harbor Capital Management LLC now owns 8,848 shares of the biotechnology company’s stock valued at $589,000 after buying an additional 952 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ascendis Pharma A/S by 153.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,444 shares of the biotechnology company’s stock valued at $598,000 after buying an additional 5,107 shares during the last quarter. Advisory Research Inc. bought a new stake in Ascendis Pharma A/S in the third quarter valued at about $838,000. Finally, DekaBank Deutsche Girozentrale increased its holdings in Ascendis Pharma A/S by 464.6% in the third quarter. DekaBank Deutsche Girozentrale now owns 27,100 shares of the biotechnology company’s stock valued at $1,916,000 after buying an additional 22,300 shares during the last quarter. 95.60% of the stock is owned by hedge funds and other institutional investors.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Recommended Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.